BPC July 05 update

Oasmia OASM shares rally 67% on agreement with largest shareholder

Price and Volume Movers

With most traders and companies taking the day off for the long weekend, Friday saw very little price moving news, with a couple exceptions, one being Tyme Technologies, Inc. (NASDAQ: TYME), which presented updated data from its open-label Phase 2 TYME-88-Panc trial in patients with advanced pancreatic cancer. Shares closed up 19% to $1.45.

Oasmia Pharmaceutical AB (NASDAQ: OASM) shares surged to close up 67% to $2.18 on news that it has reached an agreement with Arwidsro, its primary shareholder, to solve its outstanding balances. As a result, its liabilities are reduced, equity has increased and the company also receives liquidity.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Xenetic Biosciences, Inc. (XBIO): $12.25; +39%.

OHR Pharmaceutical, Inc. (OHRP): $3.70; +17%.

Karuna Therapeutics, Inc. (KRTX): $27.35; +12%.

Leap Therapeutics, Inc. (LPTX): $1.94; +11%.

Catalyst Biosciences, Inc. (CBIO): $9.31; +11%.

DECLINERS:

Melinta Therapeutics, Inc. (MLNT): $7.17; -9%.

MeiraGTx Holdings plc (MGTX): $26.95; -9%.

G1 Therapeutics, Inc. (GTHX): $27.89; -9%.

Anavex Life Sciences Corp. (AVXL): $3.47; -9%.

Sesen Bio, Inc. (SESN): $1.23; -9%.

Pipeline updates:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

CYAD – Celyad SA
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer

Phase 1 Phase 1 data to presented at ESMO July 2019 noted 1/9 partial responses, 6/9 stable disease.
$165.5 million

CYAD – Celyad SA
CYAD-101 - alloSHRINK
Colorectal cancer

Phase 1 Phase 1 data to presented at ESMO noted 1/6 partial responses and three with stable disease.
$165.5 million

TYME – Tyme Technologies Inc.
SM-88
Pancreatic cancer

Phase 2 Phase 2 updated data June 5, 2019 noted median overall survival data of 6.3 months.
$148.2 million